These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 27914096)

  • 1. Successful treatment of multiple in-transit melanomas on the leg with intensity-modulated radiotherapy and immune checkpoint inhibitors: Report of two cases.
    Fujimura T; Kambayashi Y; Furudate S; Hidaka T; Sato Y; Tanita K; Tono H; Tsukada A; Hashimoto A; Aiba S
    J Dermatol; 2017 May; 44(5):592-595. PubMed ID: 27914096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three cases of nivolumab therapy-failed advanced melanoma successfully controlled by ipilimumab with intensity-modulated radiotherapy.
    Amagai R; Fujimura T; Kambayashi Y; Sato Y; Tanita K; Hashimoto A; Aiba S
    J Dermatol; 2019 May; 46(5):449-452. PubMed ID: 30908705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffuse recurrent cutaneous melanoma of the scalp and neck successfully treated with volumetric modulated arc therapy and concurrent ipilimumab.
    Schmid RK; Harker-Murray A; Niemczyk K; Robbins JR
    Pract Radiat Oncol; 2018; 8(3):174-178. PubMed ID: 29122555
    [No Abstract]   [Full Text] [Related]  

  • 4. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
    Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C
    Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of BRAF/MEK inhibitor-resistant advanced cutaneous melanoma with nivolumab plus ipilimumab combination therapy followed by intensity-modulated radiotherapy.
    Okuma T; Furudate S; Kambayashi Y; Hashimoto A; Aiba S; Fujimura T
    J Dermatol; 2021 Sep; 48(9):1419-1422. PubMed ID: 34002878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab: A Review in Advanced Melanoma.
    Scott LJ
    Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contact immunotherapy enhances the therapeutic effects of nivolumab in treating in-transit melanoma: Two cases reports.
    Fujimura T; Furudate S; Kakizaki A; Kambayashi Y; Haga T; Hashimoto A; Aiba S
    J Dermatol; 2016 Jun; 43(6):686-9. PubMed ID: 26663262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One or Two Immune Checkpoint Inhibitors?
    Robert C; Lanoy E; Besse B
    Cancer Cell; 2019 Dec; 36(6):579-581. PubMed ID: 31951559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Not Available].
    Mateus C; Libenciuc C; Robert C
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
    Ugurel S; Kiecker F; Fröhling S; Wetter A; Bankfalvi A; Sucker A; Zimmer L; Livingstone E; Roesch A; Becker JC; Schadendorf D
    Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071
    [No Abstract]   [Full Text] [Related]  

  • 12. Nivolumab in melanoma.
    Specenier P
    Expert Rev Anticancer Ther; 2016 Dec; 16(12):1247-1261. PubMed ID: 27776441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab.
    Moreira RB; Hamieh L; Gjini E; Lako A; Krajewski KM; Yoon CH; Ott PA
    J Immunother Cancer; 2017 Jul; 5(1):61. PubMed ID: 28716097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity?
    Orloff M; Weight R; Valsecchi ME; Sato T
    Rev Recent Clin Trials; 2016; 11(2):81-6. PubMed ID: 27028970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipilimumab-Based
 Therapy: Consensus Statement From the Faculty of the Melanoma Nursing Initiative on Managing Adverse Events With Ipilimumab Monotherapy and Combination Therapy With Nivolumab.
    Madden KM; Hoffner B
    Clin J Oncol Nurs; 2017 Aug; 21(4 Suppl):30-41. PubMed ID: 28738054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity.
    Chan PY; Hall P; Hay G; Cohen VML; Szlosarek PW
    Pigment Cell Melanoma Res; 2017 Jan; 30(6):558-562. PubMed ID: 28640512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
    Zimmer L; Apuri S; Eroglu Z; Kottschade LA; Forschner A; Gutzmer R; Schlaak M; Heinzerling L; Krackhardt AM; Loquai C; Markovic SN; Joseph RW; Markey K; Utikal JS; Weishaupt C; Goldinger SM; Sondak VK; Zager JS; Schadendorf D; Khushalani NI
    Eur J Cancer; 2017 Apr; 75():47-55. PubMed ID: 28214657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of radiotherapy in the overall treatment of melanoma.
    Forschner A; Heinrich V; Pflugfelder A; Meier F; Garbe C
    Clin Dermatol; 2013; 31(3):282-9. PubMed ID: 23608447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod.
    Joseph RW; Cappel M; Tzou K; Bagaria S; Gilstrap C; Swaika A; Jambusaria-Pahlajani A
    Melanoma Res; 2016 Aug; 26(4):409-12. PubMed ID: 27138458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are checkpoint inhibitors a valuable option for metastatic or unresectable vulvar and vaginal melanomas?
    Quéreux G; Wylomanski S; Bouquin R; Saint-Jean M; Peuvrel L; Knol AC; Hanf M; Dréno B
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e39-e40. PubMed ID: 28750150
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.